Drug Type Small molecule drug |
Synonyms SYH2095 |
Target |
Action inhibitors |
Mechanism KAT6A inhibitors(lysine acetyltransferase 6A inhibitors), KAT6B inhibitors(lysine acetyltransferase 6B inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Neoplasm | Phase 1 | China | 03 Jul 2026 | |
| Locally Advanced Malignant Neoplasm | Phase 1 | China | 03 Jul 2026 | |
| Advanced cancer | IND Approval | United States | 24 Apr 2026 |





